TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04129372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Foods Take Time
Description: New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
Study: NCT03376659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 750mg IV q2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 750mg IV q2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 750mg IV q2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c.
Study: NCT03376659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg orally twice a day, Monday - Friday Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg orally twice a day, Monday - Friday Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg orally twice a day, Monday - Friday Weekly
Study: NCT02049307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study: NCT04101539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIMA-guided catheter ablation
Description: Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
Study: NCT04226274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REN001
Description: Once daily for 12 weeks
Study: NCT00680745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study: NCT04101539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVI
Description: Standard PVI for AF.
Study: NCT02654431

Intervention type: PROCEDURE
Intervention: Breast Cancer patient
Description: Samples

Intervention type: PROCEDURE
Intervention: Breast Cancer patient
Description: Samples

Intervention type: PROCEDURE
Intervention: Breast Cancer patient
Description: Samples

Intervention type: PROCEDURE
Intervention: Cancer patients
Description: Samples

Intervention type: PROCEDURE
Intervention: Cancer patients
Description: Samples
Study: NCT00680745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study: NCT03376659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV q2weeks
Study: NCT04365959

Intervention type: PROCEDURE
Intervention: Prone position
Description: The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
Study: NCT01353274

Intervention type: DRUG
Intervention: Micamlo
Description: Telmisartan plus Amlodipine T40/A5
Study: NCT03862898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar stabilization exercises
Description: Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
Study: NCT02654431

Intervention type: PROCEDURE
Intervention: Cancer patients
Description: Samples
Study: NCT03862898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
Study: NCT02430454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased cognitive load
Description: simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
Study: NCT02431767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX®-GP HIV-1 DNA vaccine
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX®-GP HIV-1 DNA vaccine
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX®-GP HIV-1 DNA vaccine
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX®-GP HIV-1 DNA vaccine
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-12 (IL-12) DNA adjuvant
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-12 (IL-12) DNA adjuvant
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-12 (IL-12) DNA adjuvant
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
Study: NCT03675321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Auricular Neurostimulation
Description: Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Neurostimulation
Description: Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
Study: NCT02808234

Intervention type: PROCEDURE
Group type: OTHER
Intervention: One or two level lumbar interbody fusion surgery
Description: One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.

Intervention type: OTHER
Group type: OTHER
Intervention: Nucel
Description: Allograft derived from human amnion and amniotic fluid
Study: NCT02177825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: oral administration
Study: NCT00856687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: Oral, two doses 12 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, two doses 12 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Oral, two doses 12 hours apart
Study: NCT00851578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN
Description: WATCHMAN LAA Closure Device
Study: NCT00648674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Applied at Day 0, possible re-application at Week 6
Study: NCT02441374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tubular mesh.
Description: Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical kinesiotherapy.
Description: Applying classical kinesiotherapy in upper limb post stroke.
Study: NCT00681941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (Renvela®)
Description: Sevelamer Carbonate Tablets Dosed Three Times A Day
Study: NCT00680745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study: NCT03010059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
Study: NCT03866239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Description: Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
Study: NCT03041961

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
Study: NCT03866239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
Study: NCT03041961

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia full spectrum
Description: Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia extract
Description: Powdered extract obtained from aronia berries (Aronia melanocarpa)
Study: NCT02431741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Study: NCT02052687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2
Study: NCT01219166

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic Cholecystectomy
Study: NCT00680745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study: NCT02052687

Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: Imiquimod cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo cream 2
Study: NCT00680745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study: NCT00137423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248 (sunitinib)
Description: 37.5 mg/day, oral, continuous daily dosing
Study: NCT03438812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone (DHEA)
Description: Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
Study: NCT00811473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Oral treatment with 150 up to 300 mg/day once daily in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment once daily in the evening
Study: NCT06759688

Intervention type: BEHAVIORAL
Intervention: Carbohydrates restriction
Description: Patients followed a low carbohydrate dietary approach (LCDs). It means lower than 130 grams carbohydrates per day with special restriction restrictions on:~* Artificial sugars (e.g., sweets, baked goods, pasta, bread).~* Also, rice, butter made from vegetable oils and all types of oils except olive oil.~They were allowed:~* All types of fresh fruits and vegetable.~* Boiled potatoes.
Study: NCT01133626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 42 days of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 42 days of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone capsules
Description: Prednisone 10 mg capsule taken each day on the last 7 days of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Prednisone Capsules
Description: Placebo prednisone capsule taken each day on the last 7 days of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prednisone Capsules
Description: Placebo prednisone capsule taken each day on the last 7 days of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
Study: NCT01126658

Intervention type: OTHER
Intervention: drainage of cerebrospinal fluid (CSF)
Description: Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
Study: NCT02851407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care